Abstract: Methods, devices and systems are disclosed for inter-app communications between software applications on a mobile communications device. In one aspect, a computer-readable medium on a mobile computing device comprising an inter-application communication data structure to facilitate transitioning and distributing data between software applications in a shared app group for an operating system of the mobile computing device includes a scheme field of the data structure providing a scheme id associated with a target software app to transition to from a source software app, wherein the scheme id is listed on a scheme list stored with the source software app; and a payload field of the data structure providing data and/or an identification where to access data in a shared file system accessible to the software applications in the shared app group, wherein the payload field is encrypted.

Abstract: The present disclosure provides a system for providing personalization for a target website. The system comprises: an artificial intelligence (AI) engine including one or more machine learning algorithm trained models for providing one or more personalization features; and a personalization module configured for integrating the one or more personalization features into the target website, wherein the one or more personalization features are rendered within a popup widget displayed over the target website.

Abstract: A compound of the general formula: wherein x is equal to or greater than 0.175 and equal to or less than 0.325 and y is equal to or greater than 0.05 and equal to or less than 0.35. In another embodiment, x is equal to zero and y is greater than 0.12 and equal to or less than 0.4. The compound is also formulated into a positive electrode for use in an electrochemical cell.

Abstract: This disclosure relates to a method for characterizing activation of an anatomical tissue subjected to contraction, aiming at providing a characterization of the contraction itself in a quantitative manner which is accurate and repeatable. The invention proposes an analysis of the activation of the anatomical structure based on instantaneous spectral contents of an activity signal from which an identification of peaks of dominant frequency characterizing the contraction throughout the anatomical tissue results. An evolution of a spatial distribution of peaks of dominant frequency throughout the anatomical tissue over time can also be monitored. The disclosure finds particular advantageous applications in provision of a mapping of activation of the anatomical tissue in order to identify a possible dysfunction, such as an arrhythmia in a cardiac tissue.

Abstract: Methods, devices and systems are disclosed for inter-app communications between software applications on a mobile communications device. In one aspect, a computer-readable medium on a mobile computing device comprising an inter-application communication data structure to facilitate transitioning and distributing data between software applications in a shared app group for an operating system of the mobile computing device includes a scheme field of the data structure providing a scheme id associated with a target software app to transition to from a source software app, wherein the scheme id is listed on a scheme list stored with the source software app; and a payload field of the data structure providing data and/or an identification where to access data in a shared file system accessible to the software applications in the shared app group, wherein the payload field is encrypted.

Abstract: Systems and methods for decoding intended symbols from neural activity in accordance with embodiments of the invention are illustrated. One embodiment includes a symbol decoding system for brain-computer interfacing, including a neural signal recorder implanted into a brain of a user, and a symbol decoder, the symbol decoder including a processor, and a memory, where the memory includes a symbol decoding application capable of directing the processor to obtain neural signal data from the neural signal recorder, estimate a symbol from the neural signal data using a symbol model, and perform a command associated with the symbol.

Abstract: Systems and methods for decoding intended symbols from neural activity in accordance with embodiments of the invention are illustrated. One embodiment includes a symbol decoding system for brain-computer interfacing, including a neural signal recorder implanted into a brain of a user, and a symbol decoder, the symbol decoder including a processor, and a memory, where the memory includes a symbol decoding application capable of directing the processor to obtain neural signal data from the neural signal recorder, estimate a symbol from the neural signal data using a symbol model, and perform a command associated with the symbol.

Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.

Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.

Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Abstract: The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Abstract: A dry pigment paint system includes dry pigment doses that may be used alone or combined with other dry pigment doses to provide a desired color when dispersed in a paint base. The system may use a plurality of dry pigment formulations, with each dry pigment formulation consisting of one or more dry pigments, generally a plurality of dry pigments. Each dry pigment dose may include a single dry pigment formulation. Each does may be a tablet, capsule or sachet. Various dose forms and dispensing systems are disclosed. Formulations of easily dispersible (ED) pigments comprising a combination of a carboxylic acid polymer and a non-ionic alkoxylated surfactant are also disclosed. The combination is used in the formulation of a plurality of pigments. The formulations are suitable for mixing with a base medium at the point-of-sale (PoS) or by the end user.

Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.

Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Abstract: The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

Abstract: A litter box kit is provided.

Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.

Abstract: Aspects of the present disclosure involve a reservation system that monitors, purchases airline tickets and/or airline reservations automatically and in real-time. One or more graphical-user interfaces are generated that reduce the time it takes for a user to identify and reserve and airline ticket.